Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

14.81
+0.13000.89%
Post-market: 14.810.00000.00%19:34 EDT
Volume:268.93K
Turnover:3.95M
Market Cap:504.93M
PE:-22.82
High:15.00
Open:14.87
Low:14.28
Close:14.68
52wk High:19.60
52wk Low:7.56
Shares:34.09M
Float Shares:23.28M
Volume Ratio:1.38
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6489
EPS(LYR):-0.6560
ROE:-111.38%
ROA:-10.02%
PB:34.93
PE(LYR):-22.58

Loading ...

Neuropace Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
May 09

Press Release: NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

Dow Jones
·
Apr 30

NeuroPace reports 82% median seizure reduction in 3-year RNS post-approval study

Reuters
·
Apr 27

NeuroPace announces annual shareholder meeting webcast

Reuters
·
Apr 22

NeuroPace to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 11

NeuroPace Earnings Call Highlights Growth And AI Push

TIPRANKS
·
Apr 02

Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE)

TIPRANKS
·
Mar 18

NeuroPace assumed with an Overweight at Wells Fargo

TIPRANKS
·
Mar 18

NeuroPace to Present at Leerink 2026 Global Healthcare Conference

Reuters
·
Mar 06

Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access

TIPRANKS
·
Mar 05

NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative

Simply Wall St.
·
Mar 05

Neuropace Chief Medical Officer Martha Morrell Disposes of Common Shares

Reuters
·
Mar 05

NeuroPace forecasts 2026 revenue of $98 million to $100 million

Reuters
·
Mar 04

NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M

TIPRANKS
·
Mar 04

NeuroPace Q4 EPS $(0.08) Beats $(0.17) Estimate, Sales $26.588M Beat $24.791M Estimate

Benzinga
·
Mar 04

BRIEF-NeuroPace, Inc. Q4 EPS USD -0.08

Reuters
·
Mar 04

Neuropace, Inc. Q4 EPS USD -0.08

THOMSON REUTERS
·
Mar 04

Neuropace Inc - Q1 2026 Revenue Guidance $21 Mln-$22 Mln

THOMSON REUTERS
·
Mar 04

Press Release: NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

Dow Jones
·
Mar 04

NeuroPace (NPCE) Receives a Buy from Lake Street

TIPRANKS
·
Mar 03